NASDAQ
84.95USD
0.00 (0.00%)
We have scored 20 news catalysts on Crinetics Pharmaceuticals, Inc. (CRNX) over the past 12 months. The biggest single-day move next to one of them came Jul 7, 2026, when CRNX closed +98.7%: “Crinetics shares surge after Vertex agrees to $10B cash buyout”. Coverage across the window leans positive (average ticker sentiment +0.34). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
9B
P/E
—
EPS
—
Beta
0.13
52W range
32.3-85.01
Day range
84.95–84.95
Open
84.95
Prev close
84.95
Volume
0
Avg volume
3.3M
Dividend
0.00
IPO
2018-07-18
Analysts publish price targets on CRNX, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
9 analyst price targets from $55 to $85
as of 2026-09-24
The market is within 0% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Crinetics Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CRNX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
The price sits exactly at the $85 median of published models, matching the all-cash acquisition offer from Vertex and indicating the market has fully accepted the deal's terms.
What the disagreement turns on
Whether the $85 per share acquisition by Vertex closes as expected; the wired data cannot measure regulatory or financing conditions, so this cannot be tested here.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
